Close
  Indian J Med Microbiol
 

Figure 2: Disease progression with increased number and size of metabolically active liver lesions after 4 months of treatment with everolimus (a, c, e); however, appearing of increased uptake on 68Ga-DOTA-Tyr3-octreotate positron emission tomography-computed tomography imaging (b and d)

Figure 2: Disease progression with increased number and size of metabolically active liver lesions after 4 months of treatment with everolimus (a, c, e); however, appearing of increased uptake on 68Ga-DOTA-Tyr3-octreotate positron emission tomography-computed tomography imaging (b and d)